RxDoctor Payments Data

Michael Green, MD

Interventional Cardiology · Springdale, ARNPI 1437193612

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Abbott at 58.3% of the total. Reporting peaked in 2019 at $3,133 and has fallen 71.2% since, to $903 in 2025.

$10,340in general payments, 2019–2025

Across 313 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Boston Scientific$1K
  • Abiomed$884
  • Amgen$754
  • Inari Medical, Inc.$620
  • Stryker$301
  • plus $449 from 7 others

What the payments were for

  • Food & beverage$10,27499%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,340 in reported general payments places this provider in the 70th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$261,922
Medicare patients
734
Services billed
2,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan342$262,024
EliquisApixaban297$229,526
XareltoRivaroxaban47$29,694
Repatha SureclickEvolocumab25$21,583
BrilintaTicagrelor31$18,286
VerquvoVericiguat22$15,942
MultaqDronedarone Hcl14$15,218
Flecainide Acetate396$13,794
SotalolSotalol Hcl352$6,272
Ranolazine ErRanolazine63$5,236
ClopidogrelClopidogrel Bisulfate680$4,795
Propafenone Hcl52$3,196
Digoxin191$3,194
Clonidine15$2,298
Isosorbide Dinitrate53$2,244

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →